IP Library Granted Patent US 7,422,739
Granted Patent B2
US 7,422,739 · App. 09/911,703 · Granted Sep 9, 2008

Anti-CD20 antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,422,739
App. No.
09/911,703
Granted
Sep 9, 2008
Kind
B2
Abstract

Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders.

Claims (13)

1. An immunologically active chimeric anti-CD20 antibody, wherein the antibody comprises a light chain variable region comprising the amino acid sequence shown as residues 23 to 128 of SEQ ID NO: 4 and a heavy chain variable region comprising the amino acid sequence shown as residues 20 to 140 of SEQ ID NO: 6.

2. The chimeric anti-CD20 antibody of claim 1 which is an IgG1.

3. A composition comprising a chimeric anti-CD20 antibody according to claim 1 and a pharmaceutically acceptable buffer.

4. The composition of claim 3 which is suitable for parenteral administration.

5. The composition of claim 4 wherein the parenteral administration is selected from the group consisting of intravenous, intramuscular, vaginal, intraperitoneal, and subcutaneous administration.

6. The composition of claim 3 which is formulated to deliver an effective dose ranging from about 0.01 to 30 mg/kg body weight upon administration to a patient.

7. The composition of claim 6 wherein the dose ranges from about 0.01 to about 25 mg/kg body weight.

8. The composition of claim 6 wherein the dose ranges from about 0.4 mg to about 20 mg/kg body weight.

9. An isolated anti-CD20 antibody, wherein the antibody comprises a light chain variable region comprising the amino acid sequence shown as residues 23 to 128 of SEQ ID NO: 4 and a heavy chain variable region comprising the amino acid sequence shown as residues 20 to 140 of SEQ ID NO: 6.

10. The anti-CD20 antibody of claim 9 wherein the antibody is murine.

11. A composition comprising an anti-CD20 antibody according to claim 9 and a pharmaceutically acceptable buffer.

12. The chimeric antibody of claim 1 wherein the antibody is not conjugated to a toxin or radioisotope.

13. The chimeric antibody of claim 1 wherein the antibody comprises a human light chain kappa constant region and a human heavy chain gamma 1 constant region.

Assignments (3)
CHANGE OF NAME Recorded Apr 30, 2015
From: BIOGEN IDEC INC.
To: BIOGEN INC.
Reel/Frame 035552/0202 →
CHANGE OF NAME Recorded Mar 18, 2008
From: IDEC PHARMACEUTICALS CORP.
To: BIOGEN IDEC INC.
Reel/Frame 020667/0643 →
MERGER Recorded Feb 12, 2008
From: IDEC PHARMACEUTICALS CORP. (CALIFORNIA)
To: IDEC PHARMACEUTICALS CORP. (DELAWARE)
Reel/Frame 020498/0550 →